Related Experiment Video
Updated: Dec 28, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Sequential Targeting in Crosslinking Nanotheranostics for Tackling the Multibarriers of Brain Tumors
Hao Wu1, Hongwei Lu1, Wenwu Xiao1
1Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, 95817, USA.
Abstract:
The efficacy of therapeutics for brain tumors is seriously hampered by multiple barriers to drug delivery, including severe destabilizing effects in the blood circulation, the blood-brain barrier/blood-brain tumor barrier (BBB/BBTB), and limited tumor uptake. Here, a sequential targeting in crosslinking (STICK) nanodelivery strategy is presented to circumvent these important physiological barriers to improve drug delivery to brain tumors. STICK nanoparticles (STICK-NPs) can sequentially target BBB/BBTB and brain tumor cells with surface maltobionic acid (MA) and 4-carboxyphenylboronic acid (CBA), respectively, and simultaneously enhance nanoparticle stability with pH-responsive crosslinkages formed by MA and CBA in situ. STICK-NPs exhibit prolonged circulation time (17-fold higher area under curve) than the free agent, allowing increased opportunities to transpass the BBB/BBTB via glucose-transporter-mediated transcytosis by MA. The tumor acidic environment then triggers the transformation of the STICK-NPs into smaller nanoparticles and reveals a secondary CBA targeting moiety for deep tumor penetration and enhanced uptake in tumor cells. STICK-NPs significantly inhibit tumor growth and prolong the survival time with limited toxicity in mice with aggressive and chemoresistant diffuse intrinsic pontine glioma. This formulation tackles multiple physiological barriers on-demand with a simple and smart STICK design. Therefore, these features allow STICK-NPs to unleash the potential of brain tumor therapeutics to improve their treatment efficacy.
Insights
A novel Sequential Targeting In Crosslinking (STICK) nanoparticle strategy effectively overcomes physiological barriers for improved brain tumor drug delivery. This approach enhances therapeutic efficacy for aggressive brain cancers like diffuse intrinsic pontine glioma.
Area of Science:
- Nanomedicine
- Biotechnology
- Oncology
Background:
- Drug delivery to brain tumors faces significant challenges from physiological barriers like the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB).
- Limited drug circulation stability and tumor cell uptake further reduce therapeutic effectiveness.
Purpose of the Study:
- To develop a nanodelivery system, Sequential Targeting In Crosslinking (STICK) nanoparticles (STICK-NPs), to overcome these barriers and enhance brain tumor treatment.
- To improve drug stability, BBB/BBTB penetration, and tumor cell targeting.
Main Methods:
- STICK-NPs were engineered with maltobionic acid (MA) and 4-carboxyphenylboronic acid (CBA) for sequential targeting and pH-responsive crosslinking.
- In vivo studies assessed circulation time, BBB/BBTB transport, tumor penetration, and therapeutic efficacy in a diffuse intrinsic pontine glioma mouse model.
Main Results:
- STICK-NPs demonstrated a 17-fold increase in circulation time compared to free agents.
- The nanoparticles successfully traversed the BBB/BBTB via glucose-transporter-mediated transcytosis and exhibited enhanced tumor cell uptake in the acidic tumor microenvironment.
- Treatment with STICK-NPs significantly inhibited tumor growth and prolonged survival with minimal toxicity.
Conclusions:
- The STICK nanodelivery strategy effectively addresses multiple physiological barriers for improved brain tumor drug delivery.
- STICK-NPs show great potential for enhancing the efficacy of therapeutics against aggressive and chemoresistant brain tumors.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024